RESUMEN
Importance: Clinical imaging trials are crucial for definitive evaluation of medical innovations, but the process is inefficient, expensive, and ethically-constrained. Virtual imaging trial (VIT) approach address these limitations by emulating the components of a clinical trial. An in silico rendition of the National Lung Screening Trial (NCLS) via Virtual Lung Screening Trial (VLST) demonstrates the promise of VITs to expedite clinical trials, reduce risks to subjects, and facilitate the optimal use of imaging technologies in clinical settings. Objectives: To demonstrate that a virtual imaging trial platform can accurately emulate a major clinical trial, specifically the National Lung Screening Trial (NLST) that compared computed tomography (CT) and chest x-ray (CXR) imaging for lung cancer screening. Design Setting and Participants: A diverse virtual patient population of 294 subjects was created from human models (XCAT) emulating the characteristics of cases on NLST, with two types of simulated lung nodules. The cohort was assessed using simulated CT and CXR systems to generate images that reflect the NLST imaging technologies. Deep learning models trained for lesion detection in CXR and CT served as virtual readers. Main Outcomes and Measures: The primary outcome was the difference in the Receiver Operating Characteristic Area Under the Curve (AUC) for CT and CXR modalities. Lesion-level AUC was aggregated to report patient-level AUC. Results: The study analyzed 294 CT and CXR simulated images from 294 virtual patients, with a lesion-level AUC of 0.81 (95% CI: 0.79-0.84) for CT and 0.56 (95% CI: 0.54-0.58) for CXR. At the patient level, CT demonstrated an AUC of 0.84 (95% CI: 0.80-0.89), compared to 0.52 (95% CI: 0.45-0.58) for CXR. Subgroup analyses on CT results indicated superior detection of homogeneous lesions (lesion-level AUC 0.97) than heterogeneous lesions (lesion-level AUC 0.72). Performance was particularly high for identifying larger nodules (AUC of 0.98 for nodules > 8 mm). The VLST results closely mirrored the NLST, particularly in size-based detection trends, with CT achieving high AUCs for nodules ≥ 8 mm and similar challenges in detecting smaller nodules. Conclusion and Relevance: The VIT results closely replicated those of the earlier NLST, underscoring its potential to replicate real clinical imaging trials. Integration of virtual trials may aid in the evaluation and improvement of imaging-based diagnosis.
RESUMEN
BACKGROUND: Photon-counting computed tomography (PCCT) has recently emerged into clinical use; however, its optimum imaging protocols and added benefits remains unknown in terms of providing more accurate lung density quantification compared to energy-integrating computed tomography (EICT) scanners. PURPOSE: To systematically assess the performance of a clinical PCCT scanner for lung density quantifications and compare it against EICT. METHODS: This cross-sectional study involved a retrospective analysis of subjects scanned (August-December 2021) using a clinical PCCT system. The influence of altering reconstruction parameters was studied (reconstruction kernel, pixel size, slice thickness). A virtual CT dataset of anthropomorphic virtual subjects was acquired to demonstrate the correspondence of findings to clinical dataset, and to perform systematic imaging experiments, not possible using human subjects. The virtual subjects were imaged using a validated, scanner-specific CT simulator of a PCCT and two EICT (defined as EICT A and B) scanners. The images were evaluated using mean absolute error (MAE) of lung and emphysema density against their corresponding ground truth. RESULTS: Clinical and virtual PCCT datasets showed similar trends, with sharper kernels and smaller voxel sizes increasing percentage of low-attenuation areas below -950 HU (LAA-950) by up to 15.7 ± 6.9% and 11.8 ± 5.5%, respectively. Under the conditions studied, higher doses, thinner slices, smaller pixel sizes, iterative reconstructions, and quantitative kernels with medium sharpness resulted in lower lung MAE values. While using these settings for PCCT, changes in the dose level (13 to 1.3 mGy), slice thickness (0.4 to 1.5 mm), pixel size (0.49 to 0.98 mm), reconstruction technique (70 keV-VMI to wFBP), and kernel (Qr48 to Qr60) increased lung MAE by 15.3 ± 2.0, 1.4 ± 0.6, 2.2 ± 0.3, 4.2 ± 0.8, and 9.1 ± 1.6 HU, respectively. At the optimum settings identified per scanner, PCCT images exhibited lower lung and emphysema MAE than those of EICT scanners (by 2.6 ± 1.0 and 9.6 ± 3.4 HU, compared to EICT A, and by 4.8 ± 0.8 and 7.4 ± 2.3 HU, compared to EICT B). The accuracy of lung density measurements was correlated with subjects' mean lung density (p < 0.05), measured by PCCT at optimum setting under the conditions studied. CONCLUSION: Photon-counting CT demonstrated superior performance in density quantifications, with its influences of imaging parameters in line with energy-integrating CT scanners. The technology offers improvement in lung quantifications, thus demonstrating potential toward more objective assessment of respiratory conditions.
